Literature DB >> 20042956

Prevalence, distribution, and morphology of ossification of the ligamentum flavum: a population study of one thousand seven hundred thirty-six magnetic resonance imaging scans.

Jiong Jiong Guo1, Keith D K Luk, Jaro Karppinen, Huilin Yang, Kenneth M C Cheung.   

Abstract

STUDY
DESIGN: Large scale, cross-sectional imaging study of a general population.
OBJECTIVES: To evaluate the prevalence, morphology, and distribution of ossification of the ligamentum flavum (OLF) in a population, and synthesize the scientific literature on the prevalence of OLF and some factors associated with its occurrence. SUMMARY OF BACKGROUND DATA: OLF is a rare disease in which the pathogenesis has not been conclusively established. Little is known about its epidemiology. To date, there is no study that comprehensively assessed the distribution and prevalence of OLF in the whole spine using magnetic resonance imaging (MRI).
METHODS: A total of 1736 southern Chinese volunteers (1068 women; 668 men) between 8 and 88 years of age (mean, 38 years) were recruited by open invitation. MRI was administered to all the participants. T2-weighted, 5-mm spin-echo MRI sequences of the whole spine were obtained. Presence of OLF was identified as an area of low signal intensity in the T2 sagittal sequence located in the posterior part of the spinal canal, and subsequently confirmed by computed tomography scans showing areas of ossification within the ligamentum flavum. The distribution of OLF was classified into 3 types: the isolated type, continuous type, and noncontinuous type. While the morphology of the lesion was classified into triangular, round, and beak shapes based on the pattern of ossification on T2-weighted sagittal MRIs.
RESULTS: OLF was identified in a total of 66 subjects or 3.8% of the population (52 women and 14 men). In 45(68.2%) cases, OLF was present at a single-level (isolated type), whereas in 21 (31.8%) cases OLF was present at multiple levels. The isolated type was found in 45 (68.2%) cases, continuous type in 11 (16.7%), and noncontinuous type in 10 (15.2%). The most common site of involvement is the lower thoracic spine, but they can also occur in the upper thoracic spine. The majority of the segments had a round morphology (n = 75: 81.5%), while 17 (18.5%) segments were triangular in shape. A literature review of the past 26 years showed only 4 reports on the prevalence of OLF, all were in special patient groups.
CONCLUSION: Case reports have described postoperative paraplegia from failure to identify and decompress all stenotic segments of OLF. This study demonstrated that OLF is not uncommon, and that some 15% of the lesions are noncontinuous, and therefore could be missed. The authors recommend that for patients undergoing surgical decompression for 1 level of OLF, the whole spine should be routinely screened for other stenotic segments. Failure to do so could result in paraplegia from the nondecompressed levels.

Entities:  

Mesh:

Year:  2010        PMID: 20042956     DOI: 10.1097/BRS.0b013e3181b3f779

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  64 in total

Review 1.  The roles of inflammatory cytokines in the pathogenesis of ossification of ligamentum flavum.

Authors:  Liang Ren; Hongtao Hu; Xianze Sun; Feng Li; Jimmy Jianheng Zhou; Yuan Min Wang
Journal:  Am J Transl Res       Date:  2013-09-25       Impact factor: 4.060

Review 2.  Rare diseases research in China: Opportunities, challenges, and solutions.

Authors:  Jinxiang Han; Yazhou Cui; Xiaoyan Zhou
Journal:  Intractable Rare Dis Res       Date:  2012-02

3.  The bridge crane technique for the treatment of the severe thoracic ossification of the ligamentum flavum with myelopathy.

Authors:  Jingchuan Sun; Kaiqiang Sun; Jiangang Shi; Ximing Xu; Yuan Wang; Qingjie Kong
Journal:  Eur Spine J       Date:  2018-06-29       Impact factor: 3.134

4.  Epidemiological survey of ossification of the ligamentum flavum in thoracic spine: CT imaging observation of 993 cases.

Authors:  Ning Lang; Hui Shu Yuan; Hong Lei Wang; Jing Liao; Man Li; Fu Xin Guo; Shan Shi; Zhong Qiang Chen
Journal:  Eur Spine J       Date:  2012-09-15       Impact factor: 3.134

5.  Multiple-level ossification of the ligamentum flavum in the cervical spine combined with calcification of the cervical ligamentum flavum and posterior atlanto-axial membrane.

Authors:  Hirokazu Inoue; Atsushi Seichi; Atsushi Kimura; Teruaki Endo; Yuichi Hoshino
Journal:  Eur Spine J       Date:  2012-10-06       Impact factor: 3.134

6.  The CT and intraoperative observation of pedicel-ossification tunnel in 151 cases of thoracic spinal stenosis from ossification of ligamentum flavum.

Authors:  Ying Zhao; Yuan Xue; Nianke Shi; Yaqi Zong; Zhong Yang; Dong He; Yi Wang; Huairong Ding; Zhiyang Li; Yanming Tang
Journal:  Eur Spine J       Date:  2014-03-08       Impact factor: 3.134

Review 7.  A systematic review of complications in thoracic spine surgery for ossification of ligamentum flavum.

Authors:  Xiaofei Hou; Zhongqiang Chen; Chuiguo Sun; Guangwu Zhang; Sijun Wu; Zheng Liu
Journal:  Spinal Cord       Date:  2017-12-28       Impact factor: 2.772

8.  Percutaneous full endoscopic posterior decompression of thoracic myelopathy caused by ossification of the ligamentum flavum.

Authors:  Bo An; Xing-Chen Li; Cheng-Pei Zhou; Bi-Sheng Wang; Hao-Ran Gao; Hai-Jun Ma; Yi He; Hong-Gang Zhou; He-Jun Yang; Ji-Xian Qian
Journal:  Eur Spine J       Date:  2019-01-17       Impact factor: 3.134

9.  Cervical Myelopathy Secondary to Combined Ossification of Ligamentum Flavum and Posterior Longitudinal Ligament-A Case Report.

Authors:  Sourabh Chachan; Niraj Sharad Kasat; Paul Thng Leong Keng
Journal:  Int J Spine Surg       Date:  2018-08-03

10.  Clinical characteristics and surgical outcome of thoracic myelopathy caused by ossification of the ligamentum flavum: a retrospective analysis of 85 cases.

Authors:  Z Li; D Ren; Y Zhao; S Hou; L Li; S Yu; T Hou
Journal:  Spinal Cord       Date:  2015-08-04       Impact factor: 2.772

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.